Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults
Public ClinicalTrials.gov record NCT07757802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Clinical Trial to Evaluate the Safety and Immunogenicity of ACU-026-001-1-Adjuvanted CH505 Protein Nanoparticles (DV901-NP) Alone or Boosted With CH505 NP (DV902-NP) or CH505 mRNAs in Adults in Overall Good Health Without HIV
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1 study will evaluate the safety, tolerability, and immune responses of investigational CH505 HIV vaccine regimens in adults in overall good health without HIV. Participants will receive CH505 protein nanoparticle vaccines (DV901-NP) formulated with the investigational adjuvant ACU-026-001-1, followed by either CH505 protein nanoparticle (DV902-NP) or CH505 mRNA vaccine boosters. The study will assess the ability of these regimens to induce HIV-specific immune responses, including B-cell responses associated with the development of broadly neutralizing antibodies. An immunology cohort will also evaluate how the location of booster vaccination affects immune responses.
Study identification
- NCT ID
- NCT07757802
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- DV901-NP Biological
- DV902-NP Biological
- CH505 TF mRNA-gp160 Biological
- CH505 w24 mRNA-gp160 Biological
- ACU-026-001-1 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2026 (Estimated)
- Primary completion
- Jun 7, 2028 (Estimated)
- Completion
- Oct 7, 2028 (Estimated)
- Last update posted
- Oct 9, 2026
2026 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bridge HIV CRS Site# 30305 | San Francisco | California | 94102 | Not yet recruiting |
| The Ponce de Leon Center CRS Site# 5802 | Atlanta | Georgia | 30308 | Not yet recruiting |
| Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Site# 30007 | Boston | Massachusetts | 02115 | Recruiting |
| BIDMC VCRS Site# 32077 | Boston | Massachusetts | 02215 | Not yet recruiting |
| University of Rochester Vaccines to Prevent HIV Infection CRS Site# 31467 | Rochester | New York | 14642 | Not yet recruiting |
| Penn Prevention CRS Site# 30310 | Philadelphia | Pennsylvania | 19104 | Not yet recruiting |
| University of Pittsburgh CRS Site# 1001 | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| Vanderbilt Vaccine (VV) CRS Site# 30352 | Nashville | Tennessee | 37232 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07757802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07757802 live on ClinicalTrials.gov.